ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Want to see ALXO full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful, reproducible efficacy signals for evorpacept combinations—especially in CD47-high, centrally confirmed HER2-positive patients—with durable responses across independent studies, a large evorpacept safety database, progressing second program (ALX2004), and strengthened corporate resources. However, the clinical findings are preliminary given small exploratory cohorts, CD47 assay/cutoff uncertainty, discordant HER2 testing, and anticipated need for a registrational trial, which introduces execution and regulatory risk. Overall, momentum and positive clinical signals outweigh the limitations, but important validation and prospective biomarker work remain.Company Guidance
Confirmed Clinical Activity of Evorpacept + Zanidatamab
Phase Ib/II exploratory results in heavily pretreated HER2-positive metastatic breast cancer (n=24) showed an overall confirmed objective response rate (ORR) of 33% (24 patients). In the 10 patients with centrally confirmed HER2-positive disease the ORR was 60%.
Strong Efficacy in CD47-High Subset
Using a retrospective cutoff of CD47 >=20%, 5 centrally confirmed HER2-positive patients were CD47-high and all 5 achieved a confirmed response (100% ORR). Median duration of response (DOR) in responders was ~20 months and median progression-free survival (PFS) in the CD47-high group was ~22 months versus 3.4 months for CD47-low.
Consistency Across Independent Studies (Breast and Gastric)
Independent data from ASPEN-06 (HER2-positive gastric randomized Phase II) showed parallel trends: ITT response rate ~41%, higher response in HER2-retained patients (~49%+), and 65% ORR in CD47-overexpressing patients. Duration of response in the gastric CD47-high subset was ~25.5 months and median PFS ~18.4 months with hazard ratio ~0.39 in that subset, reinforcing reproducibility of the CD47 signal.
Durable Responses Observed
Responders across studies exhibited long-lasting benefit with median DORs around 20 months (breast study ~20.2 months; gastric study ~25.5 months), indicating durability consistent with an immuno-oncology mechanism.
Large Evorpacept Safety Database and Differentiated MOA
Clinical safety database exceeds 800 evorpacept-treated patients. Evorpacept is engineered without an active Fc domain to avoid macrophage activation on healthy cells, aiming to mitigate on-target hematologic toxicity associated with earlier CD47 inhibitors.
ALX2004 Progressing on Schedule
ALX2004 (EGFR-targeted ADC) is advancing through dose escalation (reported escalation up to 4 mg/kg) with enrollment progressing and an initial safety readout planned in the second half of 2026.
Corporate Execution and Financing Strength
Q1 accomplishments included completion of key hires (addition of Chief Development/COO), a financing in February anchored by strong investors that strengthened the balance sheet, and enrollment progress on ASPEN-09 (Phase II breast study planned to read out ~80 patients mid-2027).
ALXO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALXO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2026 | $1.87 | $2.08 | +11.23% |
Feb 27, 2026 | $2.35 | $2.11 | -10.21% |
Nov 07, 2025 | $1.18 | $1.38 | +16.95% |
Aug 12, 2025 | $0.62 | $0.66 | +6.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ALX Oncology Holdings (ALXO) report earnings?
ALX Oncology Holdings (ALXO) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is ALX Oncology Holdings (ALXO) earnings time?
ALX Oncology Holdings (ALXO) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALXO EPS forecast?
ALXO EPS forecast for the fiscal quarter 2026 (Q2) is -0.14.